drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
A HER2-targeted bispecific antibody–drug conjugate (ADC) administered IV every 3 weeks; binds two HER2 epitopes to enhance internalization and delivers an intracellular cytotoxic payload while also inhibiting HER2 signaling and potentially mediating ADCC.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibody-Drug Conjugates
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
TQB2102 is a bispecific anti‑HER2 antibody–drug conjugate that binds two distinct HER2 epitopes to enhance receptor engagement and internalization. After HER2-mediated uptake, it releases an intracellular cytotoxic payload to kill tumor cells. The antibody component can also inhibit HER2 signaling and may trigger Fc‑mediated effector functions such as ADCC.
drug_name
TQB2102 for injection
nct_id_drug_ref
NCT06431490